The Effects of a Saffron Extract (affron®) on Menopausal Symptoms in Women during Perimenopause: A Randomised, Double-Blind, Placebo-Controlled Study by Lopresti, A.L. & Smith, S.J.
66
Received: January 13, 2021  Revised: February 28, 2021  Accepted: April 19, 2021
Address for Correspondence: Adrian L. Lopresti, Clinical Research Australia, 38 Arnisdale Road, Duncraig, WA 6023, Australia
Tel: 61-0894487376, E-mail: adrian@clinicalresearch.com.au, ORCID: https://orcid.org/0000-0002-6409-7839
ORIGINAL ARTICLE
Copyright © by The Korean Society of Meno pause
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License  (http://creativecommons.org/licenses/by-nc/4.0/).
INTRODUCTION
Based on the Staging of Reproductive Aging Work-
shop (STRAW) criteria, perimenopause is defined as 
the period between the first major variation in men-
strual cycle length (i.e., variations greater than seven 
days from the individual's normal cycle length) and 
the completion of 12 consecutive months without any 
menses [1]. The menopausal transition is associated 
with changes in sex hormones and reproductive func-
tion and is characterised by a range of menopause-spe-
cific complaints such as vasomotor symptoms (e.g., hot 
flushes and cold or night sweats), sleep disturbances, 
urogenital complaints (e.g., vaginal dryness, painful 
intercourse, and recurrent urogenital infections), breast 
pain, joint pain, changes in cognitive function and per-
formance, and mood disturbances including depressive 
and anxiety-related symptoms [2,3]. The transition into 
menopause is also associated with an increased risk of 
osteoporosis [4], metabolic disturbances [5], and car-
diovascular disease [6].
Therapeutic options for the management of meno-
pausal symptoms include hormone replacement 
therapy (HRT), pharmaceutical antidepressants, and 
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Objectives: There is preliminary evidence suggesting saffron may effectively treat menopausal symptoms. The aim of this study was to 
examine the tolerability and efficacy of a standardised saffron extract (affron®) on menopausal complaints in perimenopausal women.
Methods: In this 12-week, parallel-group, double-blind, randomised controlled trial, 86 perimenopausal women experiencing 
menopausal complaints received either a placebo or 14 mg of a saffron extract (affron®), twice daily. Outcome measures included the 
Greene Climacteric Scale (GCS), Positive and Negative Affect Schedule (PANAS), and Short Form-36 Health Survey (SF-36).
Results: Based on data collected from 82 participants, saffron was associated with greater improvements in mood and psychological 
symptoms compared to the placebo. Results from the GCS revealed a significantly greater reduction in the GCS psychological score (P 
= 0.032), characterised by a 33% reduction in anxiety and a 32% reduction in depression scores from baseline to week 12. There was 
also a significantly greater reduction in the PANAS negative affect score (P = 0.043) compared to the placebo. However, compared to 
the placebo, saffron was not associated with greater improvements in vasomotor symptoms, somatic symptoms, or other quality of life 
measures. Saffron intake was well tolerated with no reported major adverse events.
Conclusions: The saffron extract, affron®, administered for 12 weeks at a dose of 14 mg twice daily was associated with greater 
improvements in psychological symptoms. Further studies in perimenopausal women presenting with varying severity of menopausal 
symptoms, using different doses of saffron will be useful to examine in future clinical trials.
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physical activity and lifestyle changes [2,7]. Although 
effective, treatments such as HRT are associated with 
an increased risk of venous thromboembolism, stroke, 
cardiovascular disease, gallstones, and breast cancer 
[2,8-10]. Moreover, despite confirmed therapeutic 
benefits from antidepressants on depressive symptoms 
during and after the menopausal transition, it is as-
sociated with a high risk of discontinuation due to 
adverse events [11]. The most common adverse events 
identified in a meta-analysis by Wu et al. [11] included 
vomiting, nausea, constipation, lethargy, dry mouth, 
and headache, with serotonin-norepinephrine reuptake 
inhibitors (SNRIs) exhibiting a greater adverse effect 
profile compared to selective serotonin reuptake inhibi-
tors (SSRIs).
Saffron the species is derived from the stigmas of the 
Crocus sativus flower. It has traditionally been used as 
a treatment for complaints of the eye, skin, respiratory, 
gastrointestinal, and genitourinary tracts, labour pains, 
and for its mood-enhancing effects [12,13]. There is 
also an increasing body of evidence supporting its 
antidepressant and anxiolytic efficacy in adults with 
depression and anxiety [14]. In these trials, saffron was 
well-tolerated with minimal self-reported adverse ef-
fects. As a treatment for the alleviation of menopausal 
symptoms during the menopausal transition, there is 
preliminary evidence of efficacy. In a 6-week study on 
post-menopausal women with hot flushes, it was as-
sociated with reductions in hot flushes and depressive 
symptoms [15]. As a component of a multi-herbal for-
mula, saffron was also associated with improvements 
in physical and mental symptoms in post-menopausal 
women [16], and an alleviation of physical, psycho-
logical, and urogenital symptoms in perimenopausal 
women [17]. However, despite this preliminary positive 
evidence, the efficacy and safety of saffron as a stand-
alone treatment on menopausal symptoms during peri-
menopausal has not been investigated. The aim of this 
study was to examine the tolerability and efficacy of 
a standardised saffron extract (affron®) administered 




This was a two-arm, parallel-group, 12-week, ran-
domised, double-blind, placebo-controlled trial (Fig. 
1). The trial protocol was approved by the Human 
Research Ethics Committee at the National Institute 
of Integrative Medicine (approval No. 0064E_2020) 
and was prospectively registered with the Australian 
New Zealand Clinical Trials Registry (Trial ID. AC-
TRN12620000350921). All participants gave their in-
formed consent for inclusion before they participated in 
the study. The study was conducted in accordance with 
the Declaration of Helsinki. An a priori power analysis 
was undertaken to estimate the required sample size 
(based on a single outcome variable). In a randomised, 
controlled study examining the effects of saffron on 
vasomotor symptoms in postmenopausal women, an 
effect size of 0.6 compared to the placebo was identi-
fied [15]. Assuming a power of 80% and a type one 
error rate (alpha) of 5%, the number of participants 
required per group to find an effect on the Greene Cli-
macteric Scale (GCS) total score was estimated as 36. 
We planned to recruit at least 40 participants per group, 
which was hypothesised to give suitable power to find 
an effect compared to the placebo, even after dropouts.
Recruitment and randomisation
Participants were recruited across Australia through 
social media advertisements in April 2020. Interested 
participants were directed to a website landing page 
providing details about the study and a link to complete 
an initial online screening questionnaire. This online 
questionnaire screened for current climacteric symp-
toms, last menstrual cycle, changes in the menstrual 
cycle, medication use, history of medical/psychiatric 
disorders, alcohol, nicotine, and other drug use, supple-
ment and vitamin intake, and pregnancy/breastfeeding 
status. If assessed as likely eligible, volunteers partici-
pated in a phone interview with an investigator. The 
phone interview comprised a structured series of ques-
tions to further clarify details pertaining to the eligibil-
ity criteria and to obtain further demographic details. 
Suitable participants were then required to complete 
online versions of the GCS, Positive and Negative Af-
fect Schedule (PANAS), Short Form-36 Health Survey 
(SF-36), and an informed consent form. Eligible and 
consenting participants were randomly assigned to one 
of two groups (saffron or placebo) using a randomisa-
tion calculator (http://www.randomization.com). The 
randomisation calculator ensured sequence conceal-
ment. The randomisation structure comprised 8 ran-
domly permuted blocks, containing 10 participants per 
block. The participant identification number was al-
located according to the order of participant enrolment 
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in the study. All tablets were packed in identical bottles 
labelled by two intervention codes (held by the study 
sponsor until all statistical analyses were completed). 
Participants and study investigators were blind to treat-
ment group allocation until all statistical analyses were 
completed. No financial compensation was provided 
to participants for volunteering in this study, although 
at the end of the study participants allocated to the 




Female participants aged between 40 to 60 years with 
reports of changes in their menstrual cycle for at least 3 
months were recruited for this study. Participants need-
ed to have a total score of greater than 16 on the GCS, 
have an intact uterus and ovaries, a body mass index 
(BMI) between 18 and 35 kg/m2, were medication-free 
for at least 3 months (apart from the contraceptive pill 
and/or once weekly use of analgesics), were non-smok-
ers, and had no plan to commence new treatments over 
the study period. Participants were also required to be 
fluent in English and consented (via an online consent 
form) to all pertinent aspects of the trial.
Exclusion criteria 
Participants who did not have a period in the last 12 
months, were consuming more than 14 standard drinks 
of alcohol per week, had a current or illicit drug abuse 
within the last 12 months, or were suffering from medi-
cal conditions including but not limited to: diabetes, 
hyper/hypotension, cardiovascular disease, a gastroin-
testinal disease requiring regular use of medications, 
gallbladder disease/gallstones/biliary disease, endo-
crine disease, psychiatric disorder (other than mild-to-
moderate anxiety), or neurological disease (Parkinson’s 
Assessed for eligibility (n = 246)
Week 0
GCS, SF-36, PANAS
Randomized (n = 86)
Excluded (n = 160)
- Did not meet eligibility criteria (n = 138)
- Did not complete initial questionnaires (n = 22)
Week 4 (n = 41)
GCS, SF-36, PANAS
Week 8 (n = 39)
GCS, SF-36, PANAS
Week 12 (n = 39)
GCS, SF-36, PANAS
Week 4 (n = 41)
GCS, SF-36, PANAS
Week 8 (n = 38)
GCS, SF-36, PANAS
Week 12 (n = 37)
GCS, SF-36, PANAS
Discontinued (n = 2):
digestive complaints (n = 1),
no reason given (n = 1)
Discontinued (n = 2):
nausea (n = 1),
no reason given (n = 1)
Discontinued (n = 2):
unrelated hospitalisation (n = 1),
no reason given (n = 1)
Discontinued (n = 3):
n (n = 2),
job loss (n = 1)
o reason given
Discontinued (n = 1):
no reason given
Saffron (n = 43) Placebo (n = 43)
Fig. 1. Systematic illustration of study 
design. GCS: Greene Climacteric Scale, 
SF-36: Short Form-36 Health Survey, 
PANAS: Positive and Negative Affect 
Schedule.
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disease, Alzheimer’s disease, intracranial haemorrhage, 
or head or brain injury) were ineligible to participate 
in the study. Women who had any significant surgeries 
over the last year, were taking supplements that may 
affect menopausal symptoms, or were taking saffron 
supplements were also ineligible to participate in the 
study.
Interventions
Placebo and saffron tablets were identical in appear-
ance, being matched for colour coating, shape, and size. 
The active treatment, supplied by Pharmactive Biotech 
Products, SL, contained 14 mg of a standardised saffron 
extract (affron®), derived from the stigmas of C. sativus 
L. and standardised to contain > 3.5% Lepticrosalides®, 
a measure of bioactive compounds present in saffron, 
including safranal and crocin isomers. The saffron 
stigmas were cultivated in Alborea (Albacete, Spain) 
and extracted in the factory of Pharmactive Biotech 
Products, SL in Madrid (Spain) to produce affron® 
3.5% Lepticrosalides®. The placebo tablets contained 
the same excipients as the active tablet (microcrystal-
line cellulose and calcium hydrogen phosphate). All 
tablets were manufactured and packed in an Australian 
Therapeutic Goods Administration registered plant. 
All participants were mailed a 12-week supply of tab-
lets and were instructed to take one tablet, twice daily 
(morning and evening), with or without food for 12 
weeks. Medication adherence was measured by tablet 
count by the participant at week 4, 8, and 12. Efficacy 
of participant treatment blinding was examined by ask-
ing participants to predict group allocation (placebo, 
saffron, or uncertain) at the end of the study. Directions 
for use were provided on tablet bottles and participants 
were also provided with an information sheet about 
tablet intake and what to do if they missed a dose. This 
information was also verbally conveyed to participants 
during their initial telephone interview.
Outcome measures
Primary outcome measure
GCS total score: The GCS is a 21-item, validated, self-
report measure designed to assess physical and psycho-
logical symptoms associated with the transition into 
menopause. Each question is rated from zero (“not at 
all”) to three (“extremely”) with a maximum total score 
of 63. The GCS has been demonstrated to have good 
psychometric properties [18] and is sensitive to treat-
ment for menopausal symptoms [19]. The GCS was 
completed at baseline, week 4, 8, and 12.
Secondary outcome measures
GCS sub-scale scores: In addition to a total score, the 
GCS has three sub-scale scores assessing psychological 
symptoms, somatic/physical symptoms, and vasomotor 
symptoms. There is also a single question assessing in-
terest in sex. Within the psychological sub-scale, there 
are 6 questions assessing anxiety symptoms and 5 as-
sessing depressive symptoms.
PANAS: The PANAS is a validated self-report ques-
tionnaire that consists of two 10-item scales to measure 
both positive and negative affect. Each item is rated 
on a 5-point scale ranging from 1 (not at all) to 5 (very 
much). Total scores for positive and negative symptoms 
are calculated. The PANAS has robust psychometric 
properties in the general population and clinical popu-
lations presenting with anxiety, depression, and adjust-
ment disorders [20,21]. The PANAS was completed at 
baseline, week 4, 8, and 12.
SF-36: The SF-36 is a self-report, quality-of-life mea-
sure. Scores are calculated for eight areas including 
(1) energy/fatigue, (2) physical functioning, (3) bodily 
pain, (4) general health perceptions, (5) physical role 
functioning, (6) emotional role functioning, (7) social 
role functioning, and (8) emotional wellbeing. The SF-
36 is a commonly-used outcome measure with strong 
psychometric properties [22,23]. Scoring for the SF-
36 was based on the algorithm developed by RAND 
Health Care [24]. The SF-36 was completed at baseline, 
week 4, 8, and 12.
Adverse events: Tolerability and safety of tablet in-
take by participants were assessed at week 4, 8 and 12 
through an online question querying adverse effects 
that were believed to be associated with tablet intake. 
Participants were also requested to contact researchers 
immediately if any adverse effects were experienced. 
Statistical analysis
An independent samples t test was used to compare 
demographic variables across the two treatment groups 
for continuous variables, and Pearson’s chi-square was 
used to compare categorical data. To evaluate study 
objectives, a repeated-measures ANOVA was used 
to compare within-group changes over time, and the 
group (saffron versus placebo) by time interaction ef-
fect was used to assess whether changes in outcome 
scores over time were different between the two groups 
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(saffron versus placebo). All questionnaire scores were 
analysed for baseline, week 4, 8, and 12. A Cohen’s d 
was calculated to examine effect sizes. An independent-
samples t test was also undertaken to examine the per-
centage change in the GCS total score (primary study 
objective) from baseline to week 12. A further post-
hoc analysis using the independent-samples t test was 
undertaken to examine the percentage change (baseline 
to week 12) in the GCS psychological, anxiety, and de-
pression sub-scale scores.
The Shapiro–Wilk normality test was conducted to 
examine the normality of group data. This demon-
strated that data were not normally distributed, and 
this was not corrected by data transformations. How-
ever, a repeated-measures ANOVA was considered the 
most appropriate option for statistical analyses as it is 
relatively robust to violations of normality [25]. Where 
necessary, degrees of freedom were adjusted using the 
Table 1. Baseline demographic details of participants
Variable Placebo (n = 43) Saffron (n = 43) P value
Age (y) 48.63 ± 0.54 49.86 ± 0.49 0.095a
Body mass index (kg/m2) 25.78 ± 0.61 25.34 ± 0.66 0.623a
Marital status Single 8 (18.6) 6 (14.0) 0.559b
Married/de facto 35 (81.4) 37 (86.0)
Educational status Secondary 15 (34.9) 17 (39.5) 0.841b
Tertiary 18 (41.9) 18 (41.9)
Post-graduate 10 (23.3) 8 (18.6)
Exercise level Never/rarely 2 (4.7) 8 (18.6) 0.214b
1–2 times a week 3 (7.0) 4 (9.3)
3–5 times a week 18 (41.9) 14 (32.6)
≥ 6 times a week 20 (46.5) 17 (39.5)
Duration in menopausal symptoms Less than 6 mo 12 (27.9) 8 (18.6) 0.474b
6–12 mo 10 (23.3) 7 (16.3)
1–2 y 14 (32.6) 17 (39.5)
More than 2 y 7 (16.3) 11 (25.6)
GCS – total 21.98 ± 1.07 22.84 ± 1.15 0.585a
GCS – psychological 12.47 ± 0.71 12.58 ± 0.76 0.911a
GCS – somatic 4.67 ± 0.43 5.60 ± 0.44 0.133a
GCS – vasomotor 3.21 ± 0.23 2.88 ± 0.24 0.337a
PANAS – positive affect 25.81 ± 1.16 25.72 ± 1.15 0.955a
PANAS – negative affect 20.42 ± 1.20 20.23 ± 1.19 0.912a
SF-36 – physical functioning 88.49 ± 1.66 86.14 ± 2.18 0.394a
SF-36 – role limitations due to physical health 69.19 ± 5.63 71.51 ± 5.10 0.760a
SF-36 – role limitations due to emotional problems 56.53 ± 6.53 54.26 ± 6.19 0.801a
SF-36 – energy/fatigue 39.19 ± 3.30 40.70 ± 2.85 0.730a
SF-36 – emotional well-being 61.95 ± 2.79 66.42 ± 2.46 0.234a
SF-36 – social functioning 75.16 ± 3.45 79.26 ± 2.93 0.368a
SF-36 – pain 70.79 ± 3.19 66.88 ± 2.74 0.355a
SF-36 – general health 63.14 ± 2.72 66.40 ± 2.49 0.380a
Data are presented as mean ± standard error or n (%).
GCS: Greene Climacteric Scale, PANAS: Positive and Negative Affect Schedule, SF-36: Short Form-36 Health Survey.
aBy independent samples t test. bBy chi-square test. 
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Greenhouse–Geisser approach to correct for violations 
of the sphericity assumption. Data from participants 
were included in analyses of self-report outcomes if 
questionnaire data were obtained at week 4 (last obser-
vation carried forward from week 4 for missing values). 
All data were analysed using IBM SPSS Statistics (ver. 
26; IBM, Armonk, NY, USA).
RESULTS
Study population
Baseline questionnaire and demographic  
information
From 246 people who completed the initial online 
screening questionnaire, 160 individuals were either 
ineligible (n = 145) or did not complete the initial ques-
tionnaires (n = 15). The most common reasons for in-
eligibility were current medication intake, no menstrual 
cycle for greater than 1 year, BMI greater than 35 kg/
m2, hysterectomy, or diagnosis of medical conditions 
included in the exclusion criteria. Seventy-six people 
completed all study requirements and self-report data 
from 82 participants who completed at least week-4 
questionnaires were used for statistical analyses of self-
report outcome measures. Seven participants (placebo 
[n = 2] and saffron [n = 5]) failed to consume the mini-
mum number of required tablets (i.e., consumed < 80% 
of tablets). However, data from these participants were 
included in the statistical analyses as the removal of 
their results did not significantly influence statistical 
outcomes. Baseline data of these 86 participants are de-
tailed in Table 1. There were no statistically-significant, 
between-group differences at baseline. Ten participants 
withdrew from the study, 4 from the saffron group 
and 6 from the placebo group. Reasons for withdrawal 
included no reason given (placebo [n = 4] and saffron 
[n = 2]), unexpected/unrelated hospitalisation (saffron 
[n = 1]), digestive complaints (saffron [n = 1]), nausea 
(placebo [n = 1]), and job loss (placebo [n = 1]). 
Outcome measures
GCS total score (primary outcome measure)
Changes in the GCS total score across the placebo and 
saffron groups over time, repeated measures ANOVA 
significance levels, and the Cohen’s d effect size score 
are detailed in Table 2 and Figure 2. There was a statis-
tically-significant reduction in the GCS total score over 
time in both the saffron (F1.8,73 = 24.67, P < 0.001) and 
placebo group (F2.2,87 = 6.50, P = 0.002). A between-
group analysis revealed there was a non-significant 
difference in change in the total GCS score between 
the placebo and saffron group (F2,169 = 2.58, P = 0.078, 
Cohen’s d = 0.47). From baseline to week 12, there was 
a 32% reduction in the total GCS score in the saffron 
group and a 14% reduction in the placebo group. An 
independent-samples t test revealed that this difference 
was statistically significant (T[80] = 2.26, P = 0.027).
GCS sub-scale scores (secondary outcome  
measure 1)
Changes in the GCS sub-scale scores across the pla-
cebo and saffron groups over time, repeated measures 
ANOVA significance levels, and the Cohen’s d effect 
size score are detailed in Table 2 and Figure 2. A be-
tween-group analysis revealed there was a statistically-
significant difference in the change in the GCS psycho-
logical score between the placebo and saffron groups 
(F2,163 = 3.49, P = 0.032, Cohen’s d = 0.59). In both the 
saffron (F1.9,76 = 20.85, P < 0.001) and placebo groups 
(F1.9,76 = 20.85, P = 0.048) there were statistically-signif-
icant reductions in the GCS psychological score over 
time.
In the saffron group, there were statistically-signifi-
cant reductions in the somatic (F2.0,78 = 7.72, P = 0.001) 
and vasomotor (F2.6,104 = 10.74, P < 0.001) scores over 
time. In addition, there were statistically-significant 
reductions in the somatic (F2.4,98 = 5.68, P = 0.003) and 
vasomotor (F2.4,96 = 5.70, P = 0.003) scores over time in 
the placebo group. An examination of between-group 
changes revealed there were no statistically-significant, 
between-group differences in changes in the somatic 
(F2.1,175 = 0.56, P = 0.589, Cohen’s d = 0.09) or vasomo-
tor (F2.5,104 = 0.96, P = 0.401, Cohen’s d = 0.26) scores 
over time. 
A post-hoc analysis was undertaken to examine 
changes in the GCS depression and anxiety scores over 
time. In the saffron group, there was a 33% reduction 
in the anxiety and a 32% reduction in depression score 
from baseline to week 12. In the placebo group, there 
was a 7% increase in the anxiety and a 9% reduction in 
depression scores from baseline to week 12. An inde-
pendent samples t test revealed that changes in both the 
anxiety (T[80] = 2.31, P = 0.023) and depression (T[80] 
= 2.24, P = 0.028) scores were significantly greater in 
the saffron group compared to the placebo group.
https://doi.org/10.6118/jmm.21002
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PANAS scores (secondary outcome measure 2)
Changes in the PANAS negative and positive affect 
scores across the placebo and saffron groups over time, 
repeated measures ANOVA significance levels, and the 
Cohen’s d effect size score are detailed in Table 2 and 
Figure 3. A between-group analysis revealed there was 
a statistically-significant difference in the change in the 
PANAS negative score (F2.4,194 = 2.99, P = 0.043, Cohen’s 
d = 0.55) but not the PANAS positive score (F2.6,204 = 
1.74, P = 0.169, Cohen’s d = 0.29) between the placebo 
and saffron group. In the saffron group, there was a 
statistically-significant reduction in the PANAS nega-
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tive score (F2.3,93 = 8.07, P < 0.001) and statistically-sig-
nificant increase in the positive score (F2.5,101 = 9.33, P < 
0.001) over time. However, there were no statistically-
significant changes in both the PANAS negative (F2.5,99 
= 0.66, P = 0.553) and positive (F2.5,102 = 0.95, P = 0.408) 
scores in the placebo group over time.
SF-36 subscale scores (secondary outcome  
measure 3)
Changes in the SF-36 sub-scale scores across the 
placebo and saffron groups over time, repeated mea-
sures ANOVA significance levels, and the Cohen’s d 
effect size score are detailed in Table 2. Between-group 
analyses revealed there were no statistically-significant 
differences in the change in any SF-36 sub-scale score 
between the placebo and saffron groups. However, in 
the saffron group, there were statistically-significant 
improvements in the SF-36 role limitation due to emo-
tional problems (F2.3,91 = 7.41, P = 0.001), energy/fa-
tigue (F2.3,94 = 6.55, P = 0.001), and emotional wellbeing 
(F2.2,90 = 8.11, P < 0.001) sub-scale scores over time. In 
the placebo group, there was a statistically-significant 
improvement in only the pain score (F2.5,101 = 4.60, P = 
0.007) over time.
Intake of supplements
At week 12, participants recorded their quantity of 
remaining tablets. Ninety percent of participants who 
completed the study reported taking more than 80% of 
their tablets.
Efficacy of participant blinding 
To evaluate the efficacy of condition concealment 
over the study, participants were asked at the end of the 
study to predict group allocation (i.e., placebo, saffron, 
or uncertain). Efficacy of group concealment was high 
as only 8% of people in the saffron group and 28% in 
the placebo group correctly guessed treatment alloca-
tion.
Adverse events
No major adverse events were reported by participants 
although there were two withdrawals from the study 
due to mild adverse effects. One participant in the saf-
fron group withdrew due to mild digestive complaints/
bloating, and one in the placebo group withdrew due 
to ongoing nausea. The frequency of reported adverse 
effects is detailed in Table 3, which revealed an overall 
similar frequency in reported adverse events between 
the two groups. However, there was a tendency to sug-
gest greater digestive complaints in the saffron group 
(e.g., flatulence and nausea). 
DISCUSSION
In this 12-week, randomised, double-blind, placebo-
controlled study, the administration of a saffron extract 
(affron®) at a dose of 28 mg daily was associated with 
greater improvements in psychological symptoms in 
women experiencing perimenopause compared to the 
placebo. Saffron was also associated with improve-
ments in vasomotor (e.g., hot flushes and night-time 
sweating) and somatic symptoms, however, changes 
were not significantly different from the placebo. Saf-
fron intake was well tolerated with no reported major 
adverse events, although there was a greater number 
of reports of mild digestive complaints (e.g., flatulence 
and nausea).
The mood-enhancing effects of saffron have been 
confirmed in several studies. In a meta-analysis com-
prising 23 studies, saffron administration had a large 
positive treatment effect when compared with the 
placebo on depressive and anxiety symptoms [14]. 
These studies have been conducted on adults of vary-
ing ages, with no trial specifically examining its mood-
Table 3. Frequency of adverse events





Decreased appetite - 1
Body odour - 1
Migraine/headache 2 -
Dry mouth 1 -
Weight gain - 1
Pressure in head - 1
Joint pain 1 -
Nightmares - 1
Occasional hives 1 -
Fatigue - 1
Increased hot flushes - 1
Total 11 9
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enhancing effects during perimenopause. However, in 
a study on post-menopausal women with hot flushes, 
improvements in depressive symptoms were identified 
after the 6-week administration of a saffron extract 
[15]. In the current trial, saffron was associated with a 
33 and 32 percent reduction in anxiety and depressive 
symptoms, respectively, suggesting it had a generalised 
mood-enhancing effect. This is further confirmed 
by improvements in negative affective symptoms as 
measured by the PANAS. The PANAS negative affect 
score is based on ratings associated with the descriptors 
such as stressed, upset, guilty, scared, hostile, irritable, 
ashamed, nervous, jittery, and afraid. There was also 
a trend to suggest improvements in the PANAS posi-
tive symptom score, although changes did no achieve 
statistical significance compared to the placebo. Most 
improvements in self-rated mood occurred in the first 
4 weeks of the trial, with continued, albeit less pro-
nounced improvements from weeks 4 to 12. Depressive 
and anxiety symptoms during the menopausal transi-
tion are typically treated with SSRIs and SNRIs. How-
ever, although effective, they are associated with several 
adverse effects resulting in high rates of discontinua-
tion [11]. The positive mood-enhancing findings and 
low frequency of self-reported adverse effects present 
saffron as a promising natural mood treatment during 
perimenopause. 
The mechanisms associated with the antidepressant 
and anxiolytic effects of saffron have not yet been de-
termined, although it is postulated to be multifactorial. 
For example, saffron has been demonstrated to influ-
ence neurotransmitter activity, inflammation, hypotha-
lamic-pituitary-adrenal (HPA) axis activity, oxidative 
stress, mitochondrial activity, and neuroplasticity [26]. 
Disturbances in these mechanisms have been regularly 
identified in depression and anxiety [27,28]. Moreover, 
it is plausible that saffron’s mood-enhancing effects 
during perimenopause may be associated with its in-
fluence on sex hormones. In an animal study, the ad-
ministration of zearalenone (a mycotoxin with potent 
estrogenic effects) plus saffron to 8-week old female 
mice was associated with higher serum concentrations 
in luteinising hormone (LH), follicle-stimulating hor-
mone (FSH), oestradiol, and progesterone compared 
with zearalenone alone [29]. In a study on adult, female 
rats, the administration of crocin (an active constitu-
ent of saffron) decreased estrogen and progesterone 
concentrations but did not affect FSH or LH [30]. 
In a study conducted on female rats treated with the 
menopause-inducing medication cyclophosphamide, 
concentrations in oestrogen were altered by saffron 
administration but only at the highest dose of 2 g/kg/
day [31]. Finally, the oral administration of an aqueous 
saffron extract at a dose of 20 and 80 mg/kg/day for 30 
days to adult female rats increased serum concentra-
tions in FSH and progesterone (both doses), and LH 
and oestrogen (high-dose only) [32]. These animal 
studies suggest saffron may alter sex hormone concen-
trations although its effects are influenced by dose, age, 
and stressor exposure. The applicability of these animal 
studies during the menopausal transition are also un-
certain as validated menopausal animal models were 
not used [33] and the administered doses of saffron 
required to have oestrogenic effects were well beyond 
equivalent human doses used in previous human tri-
als on saffron. Whether the mood-enhancing effects of 
saffron were due to its influence on sex hormone activ-
ity could not be determined in the current study as no 
biological assessments were undertaken.
Despite previous studies demonstrating the positive 
effects of saffron, either administered alone or in com-
bination with other herbal ingredients, on vasomotor 
and somatic symptoms, such benefits were not identi-
fied in this study. In a 6-week, randomised, double-
blind, placebo-controlled trial, saffron delivered at a 
dose of 30 mg daily was associated with significant im-
provements in hot flushes in post-menopausal women 
experiencing ≥14 hot flushes per week [15]. In a 12-
week trial using multiple doses of a mixed herbal com-
bination containing saffron, fennel, and chamomile on 
peri-menopausal women, there were greater improve-
ments in physical symptoms at the high dose only and 
greater improvements in psychological and urogenital 
symptoms (e.g., sexual problems, urinary complains, 
and vaginal dryness) at the low dose only, compared to 
the placebo [17]. In another study on post-menopausal 
women, the herbal combination comprising saffron, 
tribulus terrestris, zingiber officinale (ginger), and cin-
namonum zeylanicum (cinnamon) administered for 
4 weeks was associated with greater improvements 
in physical and mental, but not urogenital symptoms 
compared to the placebo [16]. The inconsistency in 
these findings may be due to differences in the popu-
lation examined (i.e., post-menopausal vs perimeno-
pausal women), and the administration of saffron as a 
stand-alone compared to a multi-herbal combination. 
Moreover, the severity and frequency of hot flushes in 
participants recruited in the study by Kashani et al. [15] 
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were significantly greater than the levels experienced 
by the population recruited in the current trial.
Even though the results of this study add to the 
existing literature, there are several limitations and 
directions for future research. The assessment of peri-
menopause was based on self-reports of changes in 
the menstrual cycle in women aged between 40 and 60 
years. Because no formal medical assessment compris-
ing an evaluation of hormone concentrations and a 
comprehensive examination of confounding medical, 
lifestyle, and dietary factors was undertaken, it is pos-
sible that some women in other reproductive stages 
were recruited in this study. Validation of these findings 
in more comprehensively-evaluated perimenopausal 
women will be useful in future trials. 
Even though mood improvements from saffron ad-
ministration were identified, this was based on the GCS 
psychological sub-scale score and the PANAS negative 
affect score. These are validated self-report outcome 
measures but were not specifically developed for the 
assessment of depression and anxiety. Using validated, 
self-report, and clinician-administered anxiety and 
depression outcome measures will be important to use 
in future trials. Moreover, in this recruited population, 
women with severe depressive or anxiety symptoms, or 
women currently receiving psychological or pharma-
cological treatment, were excluded from participating 
in this study. The effects of saffron in women with a 
formally-diagnosed depression or anxiety-related dis-
order, and with varying levels of severity, will be useful 
to examine in future trials. 
In this study, saffron was associated with improve-
ments in vasomotor and somatic symptoms; however, 
changes were not significantly different from those 
observed in the placebo condition. In the study by 
Kashani et al. [15], a clearly-defined population of post-
menopausal women presenting with severe and fre-
quent hot flushes was recruited. However, participants 
in this study were recruited based on self-reports of 
difficulties in overall climacteric symptoms. Concern-
ing vasomotor symptoms, average ratings suggested 
symptoms were of mild-to-moderate severity and the 
frequency and severity of hot flushes were much lower 
than levels experienced by women in the Kashani et al.’s 
study [15]. An examination of the effects of saffron in 
perimenopausal women presenting with more severe, 
specific climacteric symptoms will be important to ex-
amine in future trials. The safety and efficacy of saffron 
administration in women currently receiving phar-
macological treatment for menopausal symptoms also 
require further investigation. In a previous trial, the 
adjunct administration of saffron with pharmacological 
antidepressants was associated with a greater reduction 
in depressive symptoms [34]. Its co-administration in 
perimenopausal women currently taking antidepres-
sants and/or on HRT will be important to evaluate in 
future trials. Saffron used as a component of a multi-
herbal combination also requires further investigation, 
particularly as there have been benefits identified in 
two previous trials [16,17]. Moreover, the efficacy of 
different saffron extracts should be examined. In this 
study, the standardised saffron extract, affron®, was 
used. Given the variability in the quality, purity, and 
levels of active ingredients in saffron [35], the applica-
bility of these findings to different saffron extracts or 
as a spice used in cooking is unknown. The efficacy 
and safety of saffron at different doses and treatment 
durations will also be helpful to determine whether 
higher doses or longer treatment periods are required 
for the alleviation of specific menopausal symptoms. 
As saffron was only administered for 12 weeks, an ex-
amination of its safety as a long-term treatment for cli-
macteric symptoms will also be important. Therefore, 
studies with longer follow-up are required. Finally, to 
help understand the mechanisms of action associated 
with saffron intake, assessment of changes in concen-
trations of sex hormones, and other pertinent markers 
such as those associated with inflammation, oxidative 
stress, HPA-axis activity, and neurotrophic activity will 
be useful.
The results of this 12-week trial in perimenopausal 
women provide evidence for the beneficial effects of a 
standardised saffron extract, affron®, on depressive and 
anxiety symptoms. However, its influence on vasomo-
tor or other somatic symptoms was not significantly 
different from the placebo. Given the positive, mood-
enhancing findings, further investigations into the 
benefits of saffron in more clearly-defined populations, 
presenting with specific menopausal complaints; and 
using validated self-report, clinician-administered, and 
biological outcome measures, will be important to con-
duct in future trials. 
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